Category: Press Releases

(Deutsch) Alacris Theranostics startet Seedmatch-Crowdfunding-Kampagne

Alacris Theranostics startet Seedmatch-Crowdfunding-Kampagne für einzigartige computergestützte Tumoranalyse zur Optimierung von Krebstherapien Jeder Mensch ist anders und Tumore besonders – ein Grund warum viele Krebstherapien heute immer noch scheitern. Damit der Krebs erfolgreich bekämpft werden kann, muss eine Therapie die Schwachstellen ihres Gegners erkennen können, also den individuellen Eigenheiten des Tumors angepasst werden. Alacris‘ Comprehensive […]

Read More

European Commission supports DigiTwins

European Commission supports DigiTwins On Friday, 18th of May, DigiTwins received an invitation from the European Commission to enter the next stage of the competition to become an EU Flagship for Future and Emerging Technologies. DigiTwins, a large research initiative in Europe and beyond aims at revolutionizing healthcare and biomedical research for the benefit of […]

Read More

New biomarkers for bowel cancer treatment

New biomarkers for bowel cancer treatment Scientists can predict in the lab whether a drug will be effective for individual colorectal tumors Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one of Europe’s largest […]

Read More

Alacris receives DIN EN ISO9001:2015 certification

The quality management of Alacris Theranostics GmbH has been certified by TÜV Süd according to ISO 9001:2015. Alacris therefore fulfills the requirements for a quality management system according to the latest revision of ISO 9001. Alacris focuses on personalized medicine and requires its own state-of-the-art next-generation sequencing lab with an efficient sequencing and data analysis […]

Read More

Basis for new treatment options for a fatal leukemia in children revealed

Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments Berlin, 29th July 2015 – Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells […]

Read More

Alacris wins the Deutsche Innovationspreis 2015

The Deutsche Innovationspreis 2015 was awarded in Munich on Friday, April 24th. Alacris is the proud winner in the category Small and Medium Sized Enterprises. Our innovation ModCellTM convinced the jury. They agree with us that our systems biology approach not only helps physicians and clinics to find the right drug for the right patient. […]

Read More

European consortium to validate blood-based biomarkers for cancer

Alacris is one of the partners of CANCER-ID, a newly formed European consortium funded by the Innovative Medicines Initiative (IMI). CANCER-ID consists of currently 33 partners from 13 countries aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers. The consortium brings together experts from academic and clinical research, innovative Small-to-Medium […]

Read More